Announcements
- Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
- Assembly Biosciences Announces Effective Date of Reverse Stock Split
- Assembly Biosciences Provides Anticipated Development Milestones for 2024
- Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
- Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
- Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
- Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
- Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
- Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
More ▼
Key statistics
On Friday, Assembly Biosciences Inc (V7B:FRA) closed at 11.75, 65.68% above the 52 week low of 7.09 set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.75 |
---|---|
High | 11.75 |
Low | 11.75 |
Bid | 11.85 |
Offer | 12.30 |
Previous close | 12.50 |
Average volume | 2.02k |
---|---|
Shares outstanding | 5.48m |
Free float | 3.66m |
P/E (TTM) | -- |
Market cap | 72.10m USD |
EPS (TTM) | -14.02 USD |
Data delayed at least 15 minutes, as of May 03 2024 07:06 BST.
More ▼